Straits Times Index
3,256.82 -12.45 (-0.38%) S&P 500
4,280.15 +72.88 (+1.73%) Dow
33,761.05 +424.35 (+1.27%) Nasdaq
13,047.19 +267.29 (+2.09%) BTC-USD
24,288.45 -367.46 (-1.49%) CMC Crypto 200
576.14 +4.86 (+0.85%)
Aditxt, Inc. (ADTX)
Pre-market:
| Previous close | 0.1704 |
| Open | 0.1800 |
| Bid | 0.1521 x 900 |
| Ask | 0.1799 x 1400 |
| Day's range | 0.1700 - 0.1860 |
| 52-week range | 0.1240 - 3.9500 |
| Volume | |
| Avg. volume | 6,471,604 |
| Market cap | 9.667M |
| Beta (5Y monthly) | 1.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.7200 |
| Earnings date | 13 Nov 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials
RICHMOND, Va., July 08, 2022--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, today announces that its therapeutic program Adimune™, has successfully completed a toxicology study that indicates the safety profile of ADI™-100, the Company’s immunotherapeutic technology drug that addresses rejection of transplanted organs, skin allografting, autoimmune diseas
- Business Wire
Aditxt, Inc. Partners with Guthy-Renker Affiliate GRS to Launch Consumer Awareness Campaign for AditxtScore™ to Accelerate Adoption and Revenue Growth
RICHMOND, Va., April 14, 2022--Aditxt, Inc. ("Aditxt", or the "Company") (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, today is announcing a multiyear partnership with GRS, an affiliate of marketing powerhouse Guthy-Renker, LLC ("Guthy-Renker"). This partnership will focus on building awareness and visibility among consumers and healthcare providers for the AditxtScore™ Immune Monitoring Platform. Aditxt plans to work
- Business Wire
Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th
RICHMOND, Va., April 05, 2022--Aditxt, Inc. ("Aditxt", or the "Company") (Nasdaq: ADTX) has entered into a revenue-sharing agreement with Cellvera, and certain of its affiliates. The agreement is designed to drive strategic revenue and growth starting in 2022 and provide enhanced security for the Company’s $14.5 million loan, plus interest to Cellvera Global Holdings LLC ("Cellvera"), formerly AiPharma Global Holdings LLC. The Company has signed the agreement as consideration for Aditxt’s separa
